Dr. Reddy’s Laboratories Ltd $RDY Shares Acquired by Quantinno Capital Management LP

Posted by Brenda Bartman on Aug 5th, 2026

Quantinno Capital Management LP lifted its stake in shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY – Free Report) by 71.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 637,094 shares of the company’s stock after purchasing an additional 264,856 shares during the period. Quantinno Capital Management LP’s holdings in Dr. Reddy’s Laboratories were worth $8,824,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of RDY. Invesco Ltd. increased its stake in Dr. Reddy’s Laboratories by 7.6% in the 2nd quarter. Invesco Ltd. now owns 253,342 shares of the company’s stock worth $3,808,000 after purchasing an additional 17,907 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 71.7% in the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock worth $47,000 after buying an additional 1,294 shares during the period. First Trust Advisors LP increased its position in shares of Dr. Reddy’s Laboratories by 23.3% in the second quarter. First Trust Advisors LP now owns 65,652 shares of the company’s stock worth $987,000 after acquiring an additional 12,390 shares in the last quarter. Sei Investments Co. increased its position in shares of Dr. Reddy’s Laboratories by 37.3% in the second quarter. Sei Investments Co. now owns 124,136 shares of the company’s stock worth $1,866,000 after acquiring an additional 33,747 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Dr. Reddy’s Laboratories in the 2nd quarter valued at approximately $67,000. 3.85% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Weiss Ratings lowered shares of Dr. Reddy’s Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. The Goldman Sachs Group downgraded shares of Dr. Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research note on Thursday, April 23rd. Finally, Wall Street Zen cut Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Dr. Reddy’s Laboratories has an average rating of “Reduce”.

View Our Latest Stock Report on RDY

Dr. Reddy’s Laboratories Stock Up 0.4%

Shares of Dr. Reddy’s Laboratories stock opened at $12.12 on Wednesday. The firm has a market cap of $10.11 billion, a price-to-earnings ratio of 27.53, a P/E/G ratio of 2.42 and a beta of 0.29. The stock has a 50-day simple moving average of $13.25 and a 200-day simple moving average of $13.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.90 and a quick ratio of 1.39. Dr. Reddy’s Laboratories Ltd has a 52-week low of $11.36 and a 52-week high of $15.67.

Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) last posted its earnings results on Thursday, July 23rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). Dr. Reddy’s Laboratories had a return on equity of 9.49% and a net margin of 10.15%.The business had revenue of $850.26 million during the quarter, compared to the consensus estimate of $850.56 million. On average, equities research analysts expect that Dr. Reddy’s Laboratories Ltd will post 0.47 earnings per share for the current fiscal year.

Dr. Reddy’s Laboratories Profile

(Free Report)

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.